Bristol-Myers Squibb's stock price has risen more than 25% over the past six months, reflecting significant progress in its ...

Bristol Myers Squibb (BMY) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of the factors that might affect the near-term performance of the ...

Wolfe Research has recently initiated Bristol-Myers Squibb Co (BMY) stock to Peer Perform rating, as announced on November 15, 2024, according to Finviz. Earlier, on November 13, ...

Kennedy Jr. has been a vocal critic of the pharma industry. He’s said it’s corrupted U.S. health agencies and has attacked, ...

We recently compiled a list of the 10 Best Immunotherapy Stocks to Buy Now. In this article, we are going to take a look at ...

The lawsuit accused Bristol Myers of depriving holders of "contingent value rights" (CVR) an extra $9 per share in cash by ...

“Time Off for Clinical Trials," launched on Nov. 20, sees six of BioNJ’s biggest members—Amicus Therapeutics, Bristol Myers ...

Bristol Myers Squibb (NYSE: BMY) recently reported its Q3 results, with revenues and earnings exceeding the street estimates.

In a report released today, Mohit Bansal from Wells Fargo maintained a Hold rating on Bristol-Myers Squibb (BMY – Research Report), with a ...

Novartis has teamed up with Ratio Therapeutics in a $745m licensing and collaboration agreement to advance ...

In a report released today, Srikripa Devarakonda from Truist Financial maintained a Buy rating on Bristol-Myers Squibb (BMY – Research Report). The company’s shares closed yesterday at $56.80. Don't ...

Bristol-Myers Squibb has a one year low of $39.35 and a one year high of $61.08. The stock’s 50 day simple moving average is $52.73 and its 200 day simple moving average is $47.23.